Faron pharmaceuticals was founded in 2003 in Turku, Finland. It is a clinical stage drug discovery and development company. The company focuses on acute organ traumas, vascular damage, and cancer immunotherapy. Faron pharma is most well known for Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. It also develops Clevegen, a preclinical immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule.